Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NetraMark Holdings ( (TSE:AIAI) ) has provided an announcement.
NetraMark Holdings Inc. has announced a collaboration with a leading U.S. academic medical center to advance glioblastoma research using its explainable AI platform, NetraAI. The initiative aims to identify patient subgroups and develop a therapeutic decision support tool to improve the success rate of glioblastoma clinical trials, which currently face high failure rates due to heterogeneous patient populations and limited predictive biomarkers. By analyzing longitudinal proteomic datasets, the collaboration seeks to generate insights that could optimize future trial strategies and enhance the design of targeted and efficient glioblastoma studies.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry. The company specializes in using a novel topology-based algorithm to analyze patient datasets, enabling the transformation of data into intelligent insights that enhance traditional AI/ML methods. This allows NetraMark to work with smaller datasets and accurately segment diseases and classify patients for drug sensitivity and treatment efficacy.
YTD Price Performance: 43.14%
Average Trading Volume: 53,109
Technical Sentiment Signal: Buy
Current Market Cap: C$125.3M
Find detailed analytics on AIAI stock on TipRanks’ Stock Analysis page.